Literature DB >> 21852525

Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years.

Young Kyoung Park1, Sook-In Jung2, Kyong-Hwa Park2, Dae Hun Kim1, Ji Young Choi1, Su Hwan Kim1, Kwan Soo Ko3,1.   

Abstract

Acinetobacter species have emerged as opportunistic nosocomial pathogens in intensive care units. Epidemic spread and outbreaks of multidrug-resistant or carbapenem-resistant Acinetobacter baumannii infections have been described worldwide. Species distribution, antimicrobial resistance and genotypes were investigated for Acinetobacter species isolates collected from a single institution in Korea over 7 years. Two hundred and eighty-seven Acinetobacter species isolates were collected from patients with bloodstream infections in one Korean hospital from 2003 to 2010. Most of them belonged to the Acinetobacter calcoaceticus-baumannii complex (94.4 %). The most frequently isolated species was A. baumannii (44.2 %), followed by Acinetobacter nosocomialis (formerly Acinetobacter genomic species 13TU) (34.1 %). The proportion of A. baumannii increased significantly from 2008 to 2010 (40.4 to 50.0 %). From 2008, imipenem and meropenem resistance rates increased significantly compared with 2003-2007 (12.9 % and 20.5 %, respectively, to 41.4 % and 41.5 %, respectively). An increased carbapenem resistance rate between the two periods was identified more clearly amongst A. baumannii isolates. Polymyxin-resistant A. baumannii isolates emerged in 2008-2010, despite the availability of few isolates. The increase of carbapenem resistance in A. baumannii might be due to the substitution of main clones. Although ST92 and ST69 were the most prevalent clones amongst A. baumannii in 2003-2007 (47.8 % and 15.9 %, respectively), ST75 and ST138 had increased in 2008-2010 (39.7 % and 25.9 %, respectively). Although ST92 showed moderate resistance to carbapenems, most ST75 and ST138 isolates were resistant to carbapenems. All ST75 and ST138 isolates, but only one ST92 isolate, contained the bla(OXA-23-like) gene. Increased carbapenem resistance in Acinetobacter species and A. baumannii isolates might be due to the expansion of specific carbapenem-resistant clones.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852525     DOI: 10.1099/jmm.0.033852-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

1.  A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China.

Authors:  Ting Xu; Wenying Xia; Guodong Rong; Shiyang Pan; Peijun Huang; Bing Gu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.

Authors:  Paul G Higgins; Francisco J Pérez-Llarena; Esther Zander; Ana Fernández; Germán Bou; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  AbaR-type genomic islands in non-baumannii Acinetobacter species isolates from South Korea.

Authors:  Dae Hun Kim; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

4.  Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.

Authors:  Xiaoli Zhang; Bing Gu; Yaning Mei; Yi Wen; Wenying Xia
Journal:  J Antibiot (Tokyo)       Date:  2014-09-03       Impact factor: 2.649

5.  AbaR4-type resistance island including the blaOXA-23 gene in Acinetobacter nosocomialis isolates.

Authors:  Dae Hun Kim; Ji Young Choi; Sook-In Jung; Visanu Thamlikitkul; Jae-Hoon Song; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

6.  Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: A retrospective analysis.

Authors:  Dong Xiao; Lu Wang; Daquan Zhang; Dongming Xiang; Qi Liu; Xuezhong Xing
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

7.  Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands.

Authors:  Dae Hun Kim; Ji-Young Choi; Hae Won Kim; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Visanu Thamlikitkul; Thomas Man-Kit So; Rohani M D Yasin; Po-Ren Hsueh; Celia C Carlos; Li Yang Hsu; Latre Buntaran; M K Lalitha; Jae-Hoon Song; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

8.  Nosocomial Acinetobacter baumannii Infections and Changing Antibiotic Resistance.

Authors:  Ismail Necati Hakyemez; Abdulkadir Kucukbayrak; Tekin Tas; Aslihan Burcu Yikilgan; Akcan Akkaya; Aliye Yasayacak; Hayrettin Akdeniz
Journal:  Pak J Med Sci       Date:  2013-09       Impact factor: 1.088

9.  The Changes in Epidemiology of Imipenem-Resistant Acinetobacter baumannii Bacteremia in a Pediatric Intensive Care Unit for 17 Years.

Authors:  Dongsub Kim; Haejeong Lee; Joon-Sik Choi; Christina M Croney; Ki-Sup Park; Hyo Jung Park; Joongbum Cho; Sohee Son; Jin Yeong Kim; Soo-Han Choi; Hee Jae Huh; Kwan Soo Ko; Nam Yong Lee; Yae-Jean Kim
Journal:  J Korean Med Sci       Date:  2022-06-20       Impact factor: 5.354

Review 10.  The Acinetobacter baumannii group: a systemic review.

Authors:  Hua-Zhong Zhang; Jin-Song Zhang; Li Qiao
Journal:  World J Emerg Med       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.